Otitis media vaccine - ID Biomedical

Drug Profile

Otitis media vaccine - ID Biomedical

Latest Information Update: 13 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ID Biomedical Corporation
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Otitis media; Otorhinolaryngological infections

Most Recent Events

  • 13 Mar 2008 No development reported - Preclinical for Otitis media in Canada (unspecified route)
  • 13 Mar 2008 No development reported - Preclinical for Otorhinolaryngological infections in Canada (unspecified route)
  • 08 Dec 2005 ID Biomedical Corporation is acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top